Emergent BioSolutions has secured approximately $400M in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. This includes the previously disclosed U.S. government contract modification to procure ACAM2000, as well as CNJ-016 contract options exercised in 2023 and 2024. To date in 2024, customer orders of nearly $210M have been delivered for ACAM2000 and VIGIV. For the remainder of 2024 and into 2025, Emergent is confirmed to deliver an incremental $185M+ in ACAM2000 and VIGIV orders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
- Study suggests waning mpox protection from Jynneos vaccine, CIDRAP reports
- Emergent BioSolutions falls -8.4%
- Emergent BioSolutions to settle securities class action litigation for $40M
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation